Ingalls & Snyder LLC grew its holdings in shares of Stryker Co. (NYSE:SYK) by 2.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,236 shares of the medical technology company’s stock after acquiring an additional 240 shares during the period. Ingalls & Snyder LLC’s holdings in Stryker were worth $2,569,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Coldstream Capital Management Inc. boosted its stake in Stryker by 3.3% during the 3rd quarter. Coldstream Capital Management Inc. now owns 1,706 shares of the medical technology company’s stock valued at $369,000 after purchasing an additional 54 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Stryker by 11.6% during the 3rd quarter. Quadrant Capital Group LLC now owns 530 shares of the medical technology company’s stock valued at $104,000 after purchasing an additional 55 shares during the last quarter. Benjamin Edwards Inc. boosted its stake in Stryker by 10.4% during the 3rd quarter. Benjamin Edwards Inc. now owns 617 shares of the medical technology company’s stock valued at $133,000 after purchasing an additional 58 shares during the last quarter. Everett Harris & Co. CA boosted its stake in Stryker by 1.0% during the 3rd quarter. Everett Harris & Co. CA now owns 5,759 shares of the medical technology company’s stock valued at $1,246,000 after purchasing an additional 58 shares during the last quarter. Finally, Lido Advisors LLC boosted its stake in Stryker by 2.5% during the 2nd quarter. Lido Advisors LLC now owns 2,603 shares of the medical technology company’s stock valued at $536,000 after purchasing an additional 63 shares during the last quarter. Institutional investors own 73.16% of the company’s stock.
NYSE:SYK opened at $206.75 on Thursday. The company has a current ratio of 2.18, a quick ratio of 1.35 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $78.43 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.34 and a beta of 0.76. The firm’s 50 day moving average is $206.99 and its 200 day moving average is $211.03. Stryker Co. has a 12 month low of $160.79 and a 12 month high of $223.45.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.90 by $0.01. The company had revenue of $3.59 billion for the quarter, compared to analysts’ expectations of $3.58 billion. Stryker had a net margin of 23.55% and a return on equity of 25.33%. Stryker’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.69 EPS. Research analysts predict that Stryker Co. will post 8.23 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.575 dividend. This represents a $2.30 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date is Monday, December 30th. This is a boost from Stryker’s previous quarterly dividend of $0.52. Stryker’s payout ratio is 31.46%.
In related news, COO Timothy J. Scannell sold 4,666 shares of Stryker stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $206.28, for a total value of $962,502.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Glenn S. Boehnlein sold 2,700 shares of Stryker stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $215.85, for a total transaction of $582,795.00. Following the completion of the sale, the chief financial officer now directly owns 17,933 shares in the company, valued at approximately $3,870,838.05. The disclosure for this sale can be found here. Insiders sold a total of 26,652 shares of company stock worth $5,705,481 in the last ninety days. 7.20% of the stock is currently owned by insiders.
SYK has been the subject of a number of analyst reports. Evercore ISI upgraded Stryker from an “in-line” rating to an “outperform” rating in a research note on Thursday, January 2nd. Bank of America lifted their price target on Stryker from $220.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. ValuEngine downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Piper Sandler downgraded Stryker from an “overweight” rating to a “neutral” rating and set a $210.00 price target for the company. in a research note on Tuesday, January 7th. Finally, Morgan Stanley lifted their price target on Stryker from $230.00 to $242.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Stryker presently has a consensus rating of “Buy” and an average target price of $222.16.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: Why do analysts give a neutral rating?
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.